Novo Nordisk’s Weight-Loss Drug Opens New Doors for Alzheimer’s Treatment
Chris Viehbacher, CEO of Biogen Inc., stated that a successful clinical trial for Novo Nordisk A/S’s weight-loss drug could enhance the prospects for Alzheimer’s treatments rather than pose a threat…